Phase 1 Remission Clinical Trials
10 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–10 of 10 trials
Recruiting
Phase 1
Universal CAR-T Cells Targeting Multiple Myeloma
Multiple Myeloma in Remission
Shenzhen Geno-Immune Medical Institute20 enrolled1 locationNCT06006741
Recruiting
Phase 1Phase 2
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
Acute Lymphoblastic Leukemia With Failed Remission
The First Affiliated Hospital of Soochow University196 enrolled1 locationNCT03919240
Recruiting
Phase 1Phase 2
Phase IB/II of CPX-351 for Relapse Prevention in AML
Acute Myeloid Leukemia (AML) in Remission
Georgetown University24 enrolled3 locationsNCT04990102
Recruiting
Phase 1
Ziftomenib Maintenance Post Allo-HCT
Acute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionKMT2A Rearrangement+1 more
Massachusetts General Hospital22 enrolled2 locationsNCT06440135
Recruiting
Phase 1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Acute Lymphoblastic Leukemia, in RelapseAcute Leukemia of Ambiguous LineageAcute Lymphoblastic Leukemia With Failed Remission+8 more
Andrew E. Place, MD30 enrolled5 locationsNCT05292664
Recruiting
Phase 1Phase 2
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 1
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Hematologic MalignancyGvHDGVHD,Acute+8 more
Tr1X, Inc.36 enrolled5 locationsNCT06462365
Recruiting
Phase 1
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Acute Lymphoblastic Leukemia, in RelapseB-cell Lymphoma RecurrentB-cell Lymphoma Refractory+1 more
Rong Tao48 enrolled2 locationsNCT06445803
Completed
Phase 1
A randomised, open label study to compare the bioavailability of 12mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules against the innovator 10mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules conducted under fasting condition in healthy male volunteers.
Tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARa gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. Tretinoin is for the induction of remission only.
Zenith Technology Corporation Limited18 enrolled1 locationACTRN12620000287932
Withdrawn
Phase 1
A phase I study investigating the mean circulation time, biodistribution and safety of an infusion of cultured red cells (CRC) in patients with myelodysplastic syndrome (MDS) or patients in remission from haematologic malignancy
haematologic malignancy in remission and not on active treatmentvery-low or low risk myelodysplastic syndrome
Cell Therapies Pty Ltd10 enrolled2 locationsACTRN12618000661279